You have accessJournal of UrologyKidney Cancer: Surgical Therapy II1 Apr 2015MP57-10 INITIAL CLINICAL EXPERIENCE WITH PERCUTANEOUS IRREVERSIBLE ELECTROPORATION OF KIDNEY TUMORS Monica Morgan, Aaron Lay, Asim Ozayar, Jeffrey Gahan, Clayton Trimmer, and Jeffrey Cadeddu Monica MorganMonica Morgan More articles by this author , Aaron LayAaron Lay More articles by this author , Asim OzayarAsim Ozayar More articles by this author , Jeffrey GahanJeffrey Gahan More articles by this author , Clayton TrimmerClayton Trimmer More articles by this author , and Jeffrey CadedduJeffrey Cadeddu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1998AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Percutaneous irreversible electroporation (IRE) is a novel minimally invasive technique to treat small renal masses. Electroporation causes cell death by generating an electric field across the cell, leading to creation of nano-scale pores within cellular membranes, ultimately resulting in cell apoptosis. IRE offers potential advantages to radiofrequency ablation and cryoablation since it does not rely on thermal energy. We evaluated our initial IRE experience to assess feasibility, safety, effectiveness and radiographic outcomes of IRE renal tumor ablation. METHODS A retrospective review of all IRE cases between April 2013 and October 2014 was performed. IRE was performed using the NanoKnife 15 cm monopolar probes and commercial system (AngioDynamics, NY, USA). All procedures were performed under general anesthesia. To prevent cardiac arrhythmias, IRE was synchronized with the cardiac cycle. All patients underwent CT guided ablation. To be included in analysis, patients had a minimum of 6 week follow-up with a contrast-enhanced CT. RESULTS A total of 24 tumors (23pts) underwent IRE. Mean follow-up is 8 months (2-14). Mean tumor size was 2.13 cm (1.20 - 3.60cm). Mean nephrometry score was 5.74 (4-9). Biopsy was performed in 54.5% of cases with diagnosis of renal cell carcinoma in 75.0%. There were no complications. Patients were discharged the same day 45.5% of the time, while the rest were discharged the next day. CT scan immediately post procedure typically showed decreased perfusion with an enhancing rim at the ablation site. At 6 weeks, three patients' (12.5%) CT scans demonstrated a persistent rim of enhancement, indicating ablation failure. These patients underwent successful salvage RFA. At 1 year, one patient had a recurrence that was treated with successful partial nephrectomy. CONCLUSIONS Percutaneous IRE of kidney tumors has shown to be feasible and safe. Longer term follow-up is needed to confirm the oncologic efficacy of IRE. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e693 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Monica Morgan More articles by this author Aaron Lay More articles by this author Asim Ozayar More articles by this author Jeffrey Gahan More articles by this author Clayton Trimmer More articles by this author Jeffrey Cadeddu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...